Overexpression of miR‑25 is associated with progression and poor prognosis of cholangiocarcinoma

  • Authors:
    • Haibo Liu
    • Lujuan Ma
    • Jian Wang
  • View Affiliations

  • Published online on: August 2, 2019     https://doi.org/10.3892/etm.2019.7844
  • Pages: 2687-2694
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cholangiocarcinoma (CCA) is a rare but highly aggressive type of malignancy. MicroRNA (miR)‑25 has been demonstrated to be involved in the genesis of numerous cancer types. The aim of the present study was to investigate the prognostic value and functional role of miR‑25 in CCA. The expression of miR‑25 was determined by reverse transcription‑quantitative (RT‑q)PCR. The association between miR‑25 expression and clinicopathological features was analyzed using the χ2 test. Kaplan‑Meier survival analysis and Cox linear regression were performed to explore the prognostic value of miR‑25. The effects of miR‑25 on the biological behavior of CCA cells were determined using loss‑and gain‑of‑function experiments in CCA cell lines. Upregulated miR‑25 expression was observed in CCA tissues and cell lines compared with that in the respective controls (all P<0.05). Patients with high expression of miR‑25 in CCA tissues had a comparatively higher tumor‑nodes‑metastasis stage (P=0.026), a higher rate of lymph node metastasis (P=0.032) and a shorter overall survival rate (log‑rank P=0.022). miR‑25 was determined to be an independent prognostic factor for CCA patients (P=0.036). In vitro, transfection with miR‑25 inhibitor suppressed cell viability, migration and invasion, while miR‑25 mimics had the opposite effect. These results indicated that miR‑25 functions as an oncogene and is involved in tumor progression in CCA. miR‑25 may serve as a prognostic biomarker and a potential therapeutic target for CCA treatment.
View Figures
View References

Related Articles

Journal Cover

October-2019
Volume 18 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu H, Ma L and Wang J: Overexpression of miR‑25 is associated with progression and poor prognosis of cholangiocarcinoma. Exp Ther Med 18: 2687-2694, 2019.
APA
Liu, H., Ma, L., & Wang, J. (2019). Overexpression of miR‑25 is associated with progression and poor prognosis of cholangiocarcinoma. Experimental and Therapeutic Medicine, 18, 2687-2694. https://doi.org/10.3892/etm.2019.7844
MLA
Liu, H., Ma, L., Wang, J."Overexpression of miR‑25 is associated with progression and poor prognosis of cholangiocarcinoma". Experimental and Therapeutic Medicine 18.4 (2019): 2687-2694.
Chicago
Liu, H., Ma, L., Wang, J."Overexpression of miR‑25 is associated with progression and poor prognosis of cholangiocarcinoma". Experimental and Therapeutic Medicine 18, no. 4 (2019): 2687-2694. https://doi.org/10.3892/etm.2019.7844